Introduction
X-linked severe combined immunodeficiency (XSCID) is caused by mutations in the IL2RG gene leading to absent or defective common gamma chain protein (␥ c ), a component of receptors for interleukin-2 (IL-2) and other cytokines, IL-4, IL-7, IL-9, IL-15, and IL-21. [1] [2] [3] Because ␥ c is crucial to several steps in lymphocyte development, proliferation, and activation, XSCID patients lack T cells and natural killer (NK) cells. Although B lymphocytes are present, they are nonfunctional. [4] [5] [6] [7] [8] The profound impairment of cellular and humoral immunity in XSCID patients makes them susceptible to chronic diarrhea, failure to thrive, and severe infections, often with opportunistic organisms. In the absence of immune reconstitution by allogeneic bone marrow transplantation (BMT), XSCID patients generally die within the first 2 years of life. While HLA-identical or T cell-depleted haploidentical BMT has effectively reconstituted T-cell immunity, many XSCID patients who have received transplants have predominantly hostderived B cells, fail to make specific antibodies, and depend on chronic immunoglobulin-replacement therapy. [8] [9] [10] It is not clear why BMT for XSCID and JAK3-deficient SCID, which share the T Ϫ B ϩ phenotype, has readily given rise to donor T cells, but often failed to give rise to donor B cells, whether or not cytoreductive conditioning was given prior to BMT. A long-term study of chimerism and B-cell function in post-BMT T Ϫ B ϩ SCID patients found that donor-derived B cells developed in 1 of 8 XSCID patients who did not receive conditioning and in none of 6 XSCID patients conditioned with busulfan and cyclophosphamide. 10 Gene transfer into autologous hematopoietic stem cells may become an alternative to current standard treatment with BMT or an adjunctive post-BMT therapy. The biology of ␥ c makes XSCID a favorable disease for treatment by gene therapy. Lymphocytes expressing functional ␥ c have a strong in vivo selective advantage, as demonstrated by female carriers of IL2RG mutations, whose lymphocytes have nonrandom X-chromosome inactivation with the mutation-bearing X inactive, 11 as well as by a patient who developed functional T cells following spontaneous reversion of an inherited IL2RG mutation in a lymphoid progenitor. 12 In addition, ␥ c is widely and constitutively expressed on all hematopoietic lineages and is not tightly regulated. 13, 14 Finally, because the XSCID phenotype is an immunodeficiency, immune-mediated elimination of corrected cells is not expected. Thus transfer of a correct copy of IL2RG into even a small number of long-lived, self-renewing hematopoietic stem cells could give rise to an expanded pool of lymphoid precursors and a continuous supply of functional ␥ c ϩ lymphocytes. Several in vitro studies have demonstrated retroviral transduction of normal IL2RG complementary DNA (cDNA) into B-cell lines from XSCID patients with restoration of cell-surface ␥ c and ability to respond to IL-2 and IL-4. [15] [16] [17] Immunodeficiency in mice deficient in ␥ c has also been corrected by ex vivo gene transfer, [18] [19] [20] and high-level, long-term expression of human ␥ c on lymphocytes of normal dogs has been achieved. 21 Moreover, preliminary correction of disease phenotype has occurred in 4 of 5 XSCID infants who, instead of the standard BMT treatment, received gene transfer into autologous bone marrow CD34 ϩ cells. 22, 23 The patients who demonstrated T-cell recovery following gene transfer also developed a small percentage of provirus-positive B cells and specific antibody responses during the first 2 years of follow-up. The disparity between T-cell and B-cell development from transduced ␥ c ϩ hematopoietic stem cells may be similar to that seen in post-BMT XSCID patients.
In recent work by our group, IL2RG was transduced into ␥ c Ϫ murine bone marrow, which was then transplanted into either ␥ c Ϫ or stem-cell deficient W/W v recipient mice. 20 Constructs that placed IL2RG into 5 retrovirus vector backbones showed that all gave rise to ␥ c ϩ T and B cells in ␥ c Ϫ recipients. However, only MFGS-gc (a Moloney murine leukemia virus vector modified to contain a splice site and into which IL2RG cDNA was inserted), which expressed the highest levels of ␥ c , permitted ␥ c ϩ B-cell development in W/W v recipients. The finding that MFGS-gc-transduced B-cell progenitors successfully outcompeted endogenous W/W v B progenitors suggested that high-level ␥ c expression following gene transfer into autologous hematopoietic stem cells might correct the B-cell as well as T-cell lineage in humans with XSCID.
The choice of retrovirus envelope also affects transduction efficiency of retroviral vectors into human hematopoietic progenitors. Most vectors used to date for gene transfer into human cells have had the amphotropic envelope. 24 However, transduction efficiency is poor, consistent with the very low levels of amphotropic envelope receptor expressed by highly enriched human hematopoietic cell populations. 25, 26 Therefore alternative envelopes have been considered for transduction of human hematopoietic stem cells. The gibbon ape leukemia virus (GALV) and the feline endogenous virus RD114 permit transduction of human hematopoietic cells, [27] [28] [29] [30] [31] [32] [33] [34] [35] and their receptors are expressed at higher levels than the amphotropic receptor on CD34 ϩ CD38 Ϫ human and baboon bone marrow cells. 36, 37 Retrovirus marking of human cells maturing in nonobese diabetic/SCID (NOD/SCID) mice has shown that GALV-pseudotyped viruses were more efficient than amphotropic viruses for gene transfer. 32, 33, [38] [39] [40] The GALV envelope was also superior to the amphotropic envelope in baboon studies. 41 RD114-pseudotyped vector particles demonstrated better gene transfer into human CD34 ϩ cord blood cells than either amphotropic or GALV-pseudotyped particles. 35 In the present study, we compared amphotropic, GALVpseudotyped, and RD114-pseudotyped MFGS-gc vectors by transducing autologous cells from post-BMT XSCID patients who had persistent defects in B-cell immunity or combined B-and T-cell immunity. Both XSCID B-cell lines and mobilized peripheral blood CD34 ϩ hematopoietic progenitors demonstrated provirus integration and new cell-surface ␥ c expression. The chimeric sheep model was exploited to test development of XSCID CD34 ϩ cells into mature myeloid and lymphoid lineages without and with retrovirus correction. Although human myeloid cells were recovered from sheep injected during gestation with either untransduced or transduced CD34 ϩ cells, only transduced ␥ c ϩ progenitors from XSCID patients developed into T and B cells.
Patients, materials, and methods

Human subjects, cell lines, and primary cells
Healthy volunteers and 4 XSCID patients (Table 1) were enrolled in National Institutes of Health-approved protocols with informed consent. Each of the XSCID patients, despite 1 to 4 attempted BMTs without prior cytoablative conditioning, had no specific antibody responses and continued to require immunoglobulin replacement. Epstein-Barr virus (EBV)-transformed B-cell lines had been established by standard techniques from control subjects and XSCID patients prior to BMT. 7 B-cell lines were cultured in complete medium consisting of RPMI 1640 (Life Technologies, Gaithersburg, MD) supplemented with 20% fetal bovine serum (FBS) (Hyclone, Logan, UT), 2 mM L-glutamine, and penicillin/streptomycin at 37°C, 5% CO 2 .
Volunteers and XSCID patients were given subcutaneous injections of granuloctyle colony-stimulating factor (G-CSF) (Filgrastim) (Amgen, Thousand Oaks, CA) 10 g/kg/d for 5 days. 42 On day 5, leukapheresis was performed by means of a Fenwal CS3000 continuous-flow blood cell separator (Baxter Healthcare, Deerfield, IL). CD34 ϩ cells were purified by means of the Isolex 300I paramagnetic bead immunoaffinity-positive selection system (Newell, Irvine, CA). CD34 ϩ cells were either used fresh or cryopreserved and thawed for transduction experiments. Human cord blood cells were purchased from National Disease Research Interchange (Philadelphia, PA).
DNA fingerprinting of posttransplantation XSCID patients.
Donor and recipient cells were detected by quantitative analysis of informative microsatellite DNA sequences. DNA was extracted from CD3 ϩ T cells, CD19 ϩ B cells, CD15 ϩ neutrophils, and NK cells isolated from peripheral blood with immunomagnetic beads. Similarly, CD34 ϩ hematopoetic progenitor cells were isolated from peripheral blood of the XSCID patients after treatment with G-CSF. Microsatellite sequences were amplified by polymerase chain reaction (PCR) with a multiplex kit (Ampfister Cofiler or Profiler; Perkin-Elmer Applied Biosystems, Foster City, CA). 43 PCR products were analyzed on an automated DNA sequencer (Model 310, Perkin-Elmer Applied Biosystems) with GeneScan software (ABI Prism, version 3.1, Perkin-Elmer Applied Biosystems). The proportions of amplified products representing bone marrow donor-specific and recipientspecific microsatellite alleles were calculated from the peak areas under the curves representing each allele.
MFGS-gc-pseudotyped retrovirus producer lines.
PG13 and FLYRD18 packaging cell lines were cultured in Dulbecco modified Eagle minimum essential medium supplemented with 10% newborn calf serum, 2 mM L-glutamine, and penicillin/streptomycin (Life Technologies). The 293SPA packaging cell line was cultured in improved modified Eagle medium zinc option medium with 10% FBS and 2 mM L-glutamine.
The MFGS-gc vector was generated by cloning the human IL2RG cDNA into the NcoI and BamHI sites of MFGS (Figure 1) . 20 An amphotropic MFGS-gc producer line was made by transfection of 293SPA cells with the MFGS-gc plasmid by calcium-phosphate coprecipitation followed by colony selection. GALV-pseudotyped MFGS-gc was produced by transducing PG13 packaging cells 44 with supernatant from the ecotropic GP ϩ E86 MFGS-gc. 20 RD114-pseudotyped MFGS-gc was prepared by transducing the FLYRD18 packaging cell line with supernatant from PG13 . The brightest cells were plated at limiting dilution. RNA was extracted from conditioned medium of individual clones and, for comparison, a producer line bearing IL2RG and a selectable marker for which titers had been directly measured as 1.7 ϫ 10 7 on 3T3 cells. 21 The RNA was analyzed semiquantitatively by slot blot (Schleicher & Schuell, Knee, NH), and MFGS-gc clones giving signals equal to the control were selected for subsequent experiments. All MFGS-gc producer cell lines generated sufficient titers of retrovirus particles to transduce full-length provirus into K562 cells at single-copy levels, as determined by Southern blot analysis (not shown).
Retroviral transduction
EBV-transformed B cells were cultured overnight without serum and then placed in RPMI 1640 medium supplemented with 20% FBS, 2 mM L-glutamine, and penicillin/streptomycin for 4-hour recovery at 37°C, 5% CO 2 . The cells were then cultured at 5 ϫ 10 5 /mL in 24-well polystyrene plates coated with fibronectin (Retronectin CH-296; Takara Shuzo, Otsu, Japan), in 50% filtered supernatant from amphotropic, GALV-or RD114-enveloped retrovirus producer cells supplemented with 6 g/mL polybrene (Sigma, St Louis, MO). The B cells were placed at 32°C, 5% CO 2 for 2 hours 15,21 followed by 7 hours at 37°C. Transductions of B-cell lines were performed on 2 consecutive days. Following the second transduction, cells were cultured in complete medium supplemented with IL-2 (HoffmanLaRoche, Nutley, NJ). After 2 to 3 days of growth, a third and fourth transduction were performed as above.
CD34 ϩ cells were transduced following previously described protocols. 35, 45 Briefly, purified mobilized peripheral CD34 ϩ cells were prestimulated by culturing overnight in X-Vivo 10 medium (BioWhittaker, Walkersville, MD) containing 1% human serum albumin and cytokines at 37°C in 5% CO 2 . Cytokines used for transductions with amphotropic and GALVpseudotyped viruses were Pixykine (IL-3/granulocyte-macrophage-CSF fusion protein; 50 ng/mL) (Immunex, Seattle, WA); Flt-3 ligand (100 ng/mL); and stem cell factor (SCF) (50 ng/mL). In some experiments, IL-6 (50 ng/mL), IL-3 (1 ng/mL), and G-CSF (10 ng/mL) were substituted for Pixykine. For transduction with the RD114-pseudotyped vector, the cytokine cocktail consisted of Flt-3 ligand (300 ng/mL), SCF (300 ng/mL), and IL-6 (50 ng/mL). Transductions were performed in fibronectin-coated wells with 1 to 1.5 ϫ 10 6 cells per well and 1 to 2 ϫ 10 5 cells per milliliter. Cytokines other than Pixykine were from R&D Systems (Minneapolis, MN). Following prestimulation, transductions with amphotropic and GALVpseudotyped retroviruses were performed as daily 6-to 7-hour incubations on 4 consecutive days with 90% fresh, filtered virus supernatant supplemented with 6 g/mL polybrene. RD114 transductions were performed by adding the stimulated cells to fibronectin-coated wells that had been preloaded with retroviral particles on day 2 of cytokine activation as described by Kelly et al. 35 In utero transplantation to generate human-sheep chimeras Following transduction, CD34 ϩ cells were resuspended in medium containing 10% FBS and sent by overnight mail for injection into preimmune fetal sheep at 55 to 60 days of gestation by means of the amniotic bubble procedure described previously. 46 An average of 5 ϫ 10 5 untransduced, mobilized peripheral blood CD34 ϩ cells from a healthy adult donor were injected into 3 sheep fetuses. Another sheep fetus received 1 ϫ 10 5 untransduced human cord blood CD34 ϩ cells. Two fetuses received an average of 4 ϫ 10 5 untransduced XSCID CD34 ϩ cells from patient 1; 5 fetuses each received 1.8 ϫ 10 5 RD114-transduced XSCID CD34 ϩ cells, also from patient 1. Single sheep fetuses each received either 2 ϫ 10 6 untransduced or 5 ϫ 10 6 RD114-transduced XSCID CD34 ϩ cells from patient 3.
Detection of provirus DNA
Semiquantitative PCR and Southern blot analysis were performed on DNA isolated from untransduced and transduced B-cell lines and CD34 ϩ cells of patients and healthy controls. Human lymphoid and myeloid cells were recovered from peripheral blood of human-sheep chimeras by means of serial immunomagnetic bead selection of CD3 ϩ , CD19 ϩ , CD14 ϩ , and CD45 ϩ cells (Dynabeads M-450; Dynal, Lake Success, NY).
For PCR, the 5Ј primer (5Ј-CAGTGTTTTGTGTTCAATGTCG) and 3Ј primer (5Ј-TGCAGTTTTAGCA TCTGTGTGG) were located in exons 2 and 3, respectively, of human IL2RG, allowing coamplification of both a genomic DNA segment spanning intron 2 (473 base pairs [bp] ) and a provirus cDNA segment (265 bp). Each PCR reaction contained 32 Pdeoxycytidine 5Ј-triphosphate (dCTP) and was carried out with 35 cycles of 94°C for 20 seconds, 60°C for 20 seconds, and 72°C for 1 minute. The genomic and cDNA IL2RG signals were quantitated with a Molecular Dynamics PhosphorImager and ImageQuant software (both from Molecular Dynamics, Sunnyvale, CA), with the genomic IL2RG band used as an internal control (modified from Aviles Mendoza et al 20 ) .
Southern blotting of SstI-digested DNA was performed by means of 32 P-dCTP-labeled IL2RG cDNA as a probe.
Analysis of transduced cells
Expression of ␥ c . Untransduced and transduced control and XSCID cells were stained with phycoerythrin (PE)-conjugated anti-human ␥ c after blocking with isotype control, purified rat immunoglobulin G 2b (IgG 2b ) isotype. Cells were stained for 30 minutes on ice, washed, and analyzed by either a FACScan or a FACSCalibur (Becton Dickinson) and FlowJo software (Tree Star, version 3.3.4, San Carlos, CA). Analysis was based on a live cell gate on side-scatter versus forward-scatter dot plots. The percentage of positive cells was estimated by a gate including fewer than 1.0% of cells exposed to isotype alone.
Restoration of ␥ c function. Restoration of ␥ c function following retrovirus transduction was assayed in patient B-cell lines by Western and flow cytometric analyses by means of a mouse monoclonal antibody to phosphorylated signal transducer and activator of transcription 5 (p-STAT5) antibody (Zymed Laboratories, San Francisco, CA) to detect downstream signaling following IL-2 stimulation. Cells were acid washed to remove bound cytokines, exposed to IL-2 for 10 minutes, and then probed or stained for p-STAT5. For Western blots, goat anti-mouse IgG heavy and light chain (H&L)-conjugated with horseradish peroxidase (Zymed) was used as the secondary antibody. Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG H&L (CalTag, Burlingame, CA) was used as a secondary antibody for flow cytometric analysis of p-STAT5. Isotype control for flow cytometry was FITC-conjugated mouse IgG 1 . Cells stimulated with IL-2 were compared with unstimulated cells. For flow cytometric analysis, the percentage of p-STAT5 ϩ cells was estimated by an isotype gate of fewer than 1.0%.
Analysis of ␥ c expression in human-sheep chimeras. Peripheral blood was harvested from sheep at 1 to 3 months and from selected sheep again at 10 months of age. Blood was analyzed for the presence of human cells by staining with human-specific monoclonal antibodies directly conjugated with FITC, PE, CyChrome, and allophycocyanin (APC), including CD45, CD3, CD19 CD20, CD132 (TUGh4), CD11b, and CD15 (Pharmingen). Only cells within live mononuclear cell or lymphocyte gates on side-scatter versus forward-scatter dot plots were analyzed. The overall percentage of human CD45 ϩ mononuclear cells and the percentage of CD45 ϩ mononuclear cells that were myeloid cells (CD45 ϩ CD11b ϩ CD15 ϩ , CD45 ϩ CD11b ϩ CD15 Ϫ , and CD45 ϩ CD11b Ϫ CD15 ϩ or CD45 ϩ CD3 Ϫ CD20 Ϫ ), T cells (CD45 ϩ CD3 ϩ CD19/CD20 Ϫ ), and B cells (CD45 ϩ CD19/CD20 ϩ CD3 Ϫ ) were determined. The percentages of T and B cells were calculated as the ratio of T cells to lymphoid-plus-myeloid cells and B cells to lymphoid-plus-myeloid cells. Double-gated populations (CD45 ϩ plus appropriate lymphoid or myeloid markers) were then analyzed for human ␥ c , or CD132, expression.
Statistical analysis
We performed 2 tests using the population comparison platform in the FlowJo software package. The platform allows direct comparison between different populations through the Probability Binning (Chi(T) or PB) comparison algorithm, related to the Cox 2 approach. The 2 is converted into a metric, T(), that can be used to estimate the probability that a test
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population is different from a control population. When T() ϭ 0, the 2 populations are indistinguishable (P ϭ .5). When T() ϭ 1, the populations differ by 1 SD, giving the probability that the 2 populations differ as P Ͻ .17. A T() that exceeds 4 implies that the 2 distributions are different, with P Ͻ .01 (99% confidence). All reported nonzero percentages for cell populations are statistically different from control populations.
Results
Donor cell engraftment in posttransplantation XSCID patients Table 1 (Table 1) . They continued to require immunoglobulin replacement and additional treatments as noted. Patients 2 and 3 were lymphopenic, with poor to absent T-cell responses to mitogens and antigens as compared with healthy controls.
Chimerism analysis by PCR was performed to delineate the post-BMT donor and host contributions to hematopoietic lineages in our patients (Table 1) . No patient had any detectable donorderived alleles in DNA from myeloid cells. Patient 2 had no detectable donor cell alleles in either T-or B-cell compartments. Patients 1, 3, and 4 had 5% or fewer donor B cells. The same assay was used to analyze CD34 ϩ progenitor cells purified after G-CSF mobilization and apheresis. In no patient were donor-derived hematopoietic progenitor cells detectable.
Retroviral transduction of patient cells
Titers of the producer lines were estimated by Southern blotting and RNA slot-blot analysis to be equivalent and high (see "Patients, materials, and methods"). XSCID B-cell lines were transduced as described with amphotropic, GALV-, and RD114-pseudotyped virus supernatants. With the use of coding sequence primers flanking IL2RG intron 2, genomic and provirus DNA were amplified in the same PCR reaction (Figure 2A ). Provirus equivalents per genome (relative to genomic signal) were calculated, and within each set of transductions, a relative ratio of provirus integration was obtained by normalizing to the amphotropic virus transduction rate. For all XSCID patients and controls, transduction with GALV-and RD114-pseudotyped viruses produced higher rates of provirus integration than did the amphotropic virus, with RD114 more than 10-fold higher than either of the other 2. The relative amounts of provirus integration were further analyzed by Southern blot, confirming that the RD114 envelope afforded the most provirus integration, followed by GALV and then amphotropic ( Figure 2B) . Table 2) .
Restoration of ␥ c function in XSCID cells following retrovirus transduction
To test integrity of the ␥ c signaling pathway, we took advantage of the specificity of the interaction of ␥ c with JAK3 and the subsequent activation of STAT5, using IL-2-induced pSTAT5 as an indicator of ␥ c signal transduction. Trace amounts of pSTAT5 induced by IL-2 exposure were detected in cells transduced with amphotropic-enveloped MFGS-gc. Higher amounts of pSTAT5 production on average were achieved with GALV MFGS-gc, but the highest proportion of pSTAT5 ϩ cells was seen following transduction with RD114 MFGS-gc. In the latter cells, the levels of pSTAT5 were comparable to those seen in cells from normal controls ( Figure 4A ). For the XSCID B-cell line of patient 3 with truncated ␥ c , detection of pSTAT5 was more informative than cell-surface staining for ␥ c .
Engraftment and lineage development of human cells in sheep
To evaluate whether transduced ␥ c -deficient CD34 ϩ cells could differentiate into T and B lymphocytes, thus demonstrating correction of the XSCID defect, we transplanted the human cells into fetal sheep to create stable chimeras. In a preliminary experiment (Table  3) , we compared CD34 ϩ cells from normal cord blood, known to have high numbers of hematopoietic stem cells, to peripheral blood CD34 ϩ cells obtained from a healthy donor using our G-CSF mobilization protocol. Immunomagnetic bead-selected CD34 ϩ cells from freshly harvested cord blood were cultured for 4 days in cytokine-supplemented medium and then injected into a preimmune sheep fetus. Another sheep fetus received cytokine-cultured mobilized peripheral blood CD34 ϩ cells from a healthy adult. At 1 month after birth of the sheep, their peripheral blood was analyzed for human cell engraftment. Comparable levels of chimerism were found in the recipient of cord blood and of peripheral blood, 3.0% and 2.7%, respectively (Table 3) . Similar percentages of humanderived cells were also found in the T-cell, B-cell, and myeloid lineages. The ␥ c -expression profiles of human lymphoid and myeloid cells were similar in the sheep engrafted with cord blood and peripheral blood CD34 ϩ cells (not shown). Untransduced XSCID peripheral CD34 ϩ cells from patient 1 and patient 3 and the same cells transduced with RD114 MFGS-gc were transplanted into preimmune fetal sheep to generate humansheep hematopoietic chimeras. Flow cytometric analyses of peripheral blood obtained postnatally from the sheep are summarized in Table 4 . The mononuclear cells bearing human-specific CD45 ranged from 1.4% to 5.1%. The 5 sheep that received identical aliquots of 1.8 ϫ 10 5 transduced cells from patient 1 had engraftment of CD45 ϩ human leukocytes varying from 2.0% to 5.1%, and 
similar proportions of mature human lineages. As expected, untransduced and transduced XSCID CD34 ϩ cells were equally capable of development into human myeloid cells, demonstrated with CD11b and/or CD15, accounting for 47% to 95% of the human leukocytes. As illustrated in Figure 5 Since the first successful BMT for XSCID was reported in 1968, 47 BMT has become the standard treatment. Techniques such as T-cell depletion have improved BMT outcome for patients without an HLA-matched sibling donor, making possible survival of up to 70% to 90% or more of infants with XSCID. 8, 48, 49 However, immune reconstitution, especially of specific antibody production by B cells, remains incomplete in many post-BMT XSCID patients, [8] [9] [10] a finding possibly related to their ability to make ␥ c Ϫ B cells that are nonfunctional. Therapeutic gene transfer into autologous hematopoietic stem cells has now been carried out with promising early results by Cavazzana-Calvo et al, 22 who substituted ex vivo retroviral correction of aspirated autologous bone marrow for BMT in newly diagnosed infants. Whether gene therapy may prove superior to BMT as primary treatment for XSCID remains to be shown; even the preliminary success of gene transfer in 4 of 5 XSCID infants resulted in low levels of corrected B lymphocytes. 23 However, another role for gene transfer in the Successful retroviral gene transfer depends on several factors involving the retrovirus vector and the target cell. The impact of retrovirus vector backbone on transgene expression was recently highlighted in a murine transplantation model by Aviles Mendoza et al. 20 In a comparison of 5 retrovirus vectors containing IL2RG cDNA, the highest transgene expression level, achieved by MFGSgc, was required to overcome competition with endogenous B-lymphoid progenitors to produce B cells in unirradiated W/W v hosts. We have now extended these findings by testing the hypothesis that MFGS-gc viruses of equivalent titer, but with different pseudotypes, would transduce human hematopoietic stem cells with varying efficiency and thus lead to varying degrees of functional restoration. DNA analysis of provirus in transduced patient cells illustrated the significant differences between amphotropic, GALV-pseudotyped, and RD114-pseudotyped retrovirus transduction efficiencies. As reflected in the relative ratios of provirus equivalents per genome, RD114 facilitated the transduction of the highest proportion of target cells. 35 The differences observed in provirus integration paralleled the relative levels of retrovirus receptor mRNA expressed in successive enrichments for hematopoietic stem cells (D.M.B., unpublished data, December 2001). The most striking finding on DNA analysis of cells transduced with RD114-enveloped virus was that the provirus per copy number was greater than 1 (the signal from provirus cDNA exceeded that from genomic DNA). The improvement in transduction efficiency over amphotropic-enveloped virus that was achieved with the GALV and RD114 envelopes was further confirmed by analyses of new ␥ c cell-surface expression and functional ␥ c response to stimulation with IL-2. These results suggest that the RD114 receptor, a neutral amino-acid transporter, is expressed at higher levels in human hematopoietic progenitor cells than the phosphate transporters that serve as receptors for amphotropic and GALV-enveloped retrovirus particles. Our findings are consistent with those of Kelly et al, 35 who demonstrated in a NOD/SCID repopulating assay that RD114-pseudotyped vector particles were more efficient for gene transfer into human cord blood hematopoietic stem cells than were amphotropic, GALV-pseudotyped, or VSVG-pseudotyped particles. The improvement in transduction efficiency achieved with the RD114 envelope may be as significant for in vivo selection of ␥ c ϩ -transduced cell lineages as the previously demonstrated mRNA expression levels from constructs with MFGS versus other retrovirus backbones.
The human-sheep hematopoietic chimera, an excellent model for studying human hematopoietic stem cell engraftment and maturation, has become an important tool for our preclinical evaluation of gene therapy strategies for XSCID. Despite reported phenotypic and functional differences among progenitors from mobilized peripheral blood, cord blood, and bone marrow, [50] [51] [52] [53] we achieved equivalent human lymphoid and myeloid cell development in sheep transplanted with cord blood or mobilized peripheral CD34 ϩ cells from healthy human donors, and we showed durable human chimerism lasting for 10 months. These findings suggest that peripheral mobilized CD34 ϩ cells are appropriate target cells for a human XSCID gene transfer trial. The sheep model also allowed us to demonstrate directly the successful development of BLOOD, 1 JULY 2002 ⅐ VOLUME 100, NUMBER 1 For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From
